Regulus reports positive findings from Phase I kidney disease trial

Regulus Therapeutics has reported positive topline findings from its Phase I single-ascending dose (SAD) clinical trial of RGLS8429 to treat autosomal dominant polycystic kidney disease (ADPKD).

In the trial, 32 participants received either RGLS8429 or a placebo.